ATE540928T1 - Isochinolinverbindungen und ihre medizinische verwendung - Google Patents
Isochinolinverbindungen und ihre medizinische verwendungInfo
- Publication number
- ATE540928T1 ATE540928T1 AT03774144T AT03774144T ATE540928T1 AT E540928 T1 ATE540928 T1 AT E540928T1 AT 03774144 T AT03774144 T AT 03774144T AT 03774144 T AT03774144 T AT 03774144T AT E540928 T1 ATE540928 T1 AT E540928T1
- Authority
- AT
- Austria
- Prior art keywords
- compound
- prophylaxis
- agent
- treatment
- adp
- Prior art date
Links
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical class C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000011321 prophylaxis Methods 0.000 abstract 3
- 238000011282 treatment Methods 0.000 abstract 3
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 2
- 206010008118 cerebral infarction Diseases 0.000 abstract 2
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 2
- 229940123066 Polymerase inhibitor Drugs 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000035874 hyperreactivity Effects 0.000 abstract 1
- -1 isoquinoline compound Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002340174 | 2002-11-22 | ||
| PCT/JP2003/014904 WO2004048339A1 (ja) | 2002-11-22 | 2003-11-21 | イソキノリン化合物及びその医薬用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE540928T1 true ATE540928T1 (de) | 2012-01-15 |
Family
ID=32375814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03774144T ATE540928T1 (de) | 2002-11-22 | 2003-11-21 | Isochinolinverbindungen und ihre medizinische verwendung |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7501412B2 (enExample) |
| EP (1) | EP1566380B1 (enExample) |
| JP (1) | JP4567460B2 (enExample) |
| AT (1) | ATE540928T1 (enExample) |
| AU (1) | AU2003284632A1 (enExample) |
| CA (1) | CA2507027C (enExample) |
| ES (1) | ES2376166T3 (enExample) |
| TW (1) | TW200412959A (enExample) |
| WO (1) | WO2004048339A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2380917T3 (es) | 2002-10-01 | 2012-05-21 | Mitsubishi Tanabe Pharma Corporation | Compuestos de isoquinolina y su uso medicinal |
| KR101118582B1 (ko) | 2003-11-20 | 2012-02-27 | 얀센 파마슈티카 엔.브이. | 폴리(ａｄｐ-리보스)폴리머라제 저해제로서의 6-알케닐 및6-페닐알킬 치환된 2-퀴놀리논 및 2-퀴녹살리논 |
| BRPI0416532A (pt) * | 2003-12-05 | 2007-01-09 | Janssen Pharmaceutica Nv | 2-quinolinonas e 2-quinoxalinonas substituìdas por 6 como inibidores da poli(adp-ribose) polimerase |
| WO2005113540A1 (ja) * | 2004-05-20 | 2005-12-01 | Mitsubishi Pharma Corporation | イソキノリン化合物及びその医薬用途 |
| AU2006259525B2 (en) * | 2005-06-14 | 2012-05-24 | Gpcr Therapeutics, Inc | Pyrimidine compounds |
| US8193206B2 (en) * | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
| BRPI0706726B8 (pt) | 2006-01-24 | 2021-05-25 | Janssen Pharmaceutica Nv | benzimidazóis 2-substituídos como modulares seletivos de receptor de andrógeno (sarms), composição farmacêutica que os compreende e processo para preparar |
| RU2008136784A (ru) | 2006-02-15 | 2010-03-20 | Абботт Лаборэтриз (Us) | Пиразолохинолоновые соединения, фармацевтическая композиция на их основе, способ ингибирования поли(адф-рибоза)полимеразы (parp) и способы лечения воспаления, сепсиса, септического шока и рака |
| WO2007112347A1 (en) * | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2008082887A2 (en) * | 2006-12-28 | 2008-07-10 | Abbott Laboratories | Inhibitors of poly(adp-ribose)polymerase |
| US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
| CN103432133B (zh) | 2007-01-22 | 2016-08-10 | Gtx公司 | 核受体结合剂的用途 |
| HRP20120346T1 (hr) | 2007-03-08 | 2012-05-31 | Janssen Pharmaceutica N.V. | Derivati kinolinona kao parp i tank inhibitori |
| US8404713B2 (en) * | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| WO2009155413A1 (en) | 2008-06-19 | 2009-12-23 | Wyeth | Thienyl- and furanyl-isoquinolinones and methods for using them |
| SA109300394B1 (ar) * | 2008-06-19 | 2013-01-22 | ويث | ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها |
| WO2010029048A1 (en) * | 2008-09-09 | 2010-03-18 | Sekmed Srl | 1, 2, 5-thiadiazole derivatives useful as immune potentiators |
| WO2010056847A2 (en) * | 2008-11-13 | 2010-05-20 | Taigen Biotechnology Co., Ltd. | Lyophilization formulation |
| TWI499418B (zh) * | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| US9249172B2 (en) | 2010-05-24 | 2016-02-02 | Hande Pharma Limited | Pyrazole derivatives |
| AU2014320149A1 (en) * | 2013-09-11 | 2016-04-07 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| WO2017013593A1 (en) | 2015-07-22 | 2017-01-26 | Lupin Limited | Isoquinolinone derivatives as parp inhibitors |
| SI3325623T1 (sl) | 2015-07-23 | 2019-11-29 | Inst Curie | Uporaba kombinacije molekule DBAIT in inhibitorjev PARP za zdravljenje raka |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| US20200129476A1 (en) | 2017-04-28 | 2020-04-30 | Akribes Biomedical Gmbh | PARP Inhibitor in Combination with a Glucocorticoid and/or Ascorbic Acid and/or a Protein Growth Factor for the Treatment of Impaired Wound Healing |
| AU2019235337A1 (en) | 2018-03-13 | 2020-08-27 | Centre National De La Recherche Scientifique | A Dbait molecule against acquired resistance in the treatment of cancer |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2024261243A1 (en) | 2023-06-21 | 2024-12-26 | Hemispherian As | Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1062357A (en) | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
| DE2121031A1 (en) | 1971-04-29 | 1972-11-02 | Dr. Karl Thomae Gmbh, 7950 Biberach | Base-substd quinazolines - thrombocyte aggregation inhibitors |
| IT1054655B (it) | 1975-08-27 | 1981-11-30 | Lepetit Spa | Derivati condensati del l isochinolina |
| JPS52156876A (en) | 1976-06-23 | 1977-12-27 | Mitsui Toatsu Chem Inc | Preparation of novel isoquinolone |
| JPS52156875A (en) | 1976-06-23 | 1977-12-27 | Mitsui Toatsu Chem Inc | Preparation of novel isoquinolone derivatives |
| JPS5484597A (en) | 1977-12-15 | 1979-07-05 | Yamanouchi Pharmaceut Co Ltd | Novel heterocyclic compound and its preparation |
| EP0005745B1 (en) | 1978-05-26 | 1982-07-14 | Gruppo Lepetit S.P.A. | Pyrazolo (3,4-c) and thiazolo (5,4-c) isoquinolines, methods for preparing them, these compounds for use as antiinflammatory, cns-depressant and anti-anxiety agents and pharmaceutical compositions thereof |
| JPS6442472U (enExample) | 1986-06-14 | 1989-03-14 | ||
| US4808595A (en) * | 1986-12-24 | 1989-02-28 | Merck & Co., Inc. | Furopyridine sulfonamides and their opthalmological compositions |
| ES2067508T3 (es) | 1988-08-19 | 1995-04-01 | Warner Lambert Co | Dihidroisoquinolinonas sustituidas y compuestos relacionados como potenciadores de los efectos letales de la radiacion y de ciertos agentes quimioterapeuticos; compuestos seleccionados, analogos y proceso. |
| AU8784698A (en) * | 1997-08-15 | 1999-03-08 | Johns Hopkins University, The | Method of using selective parp inhibitors to prevent or treat neurotoxicity |
| US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| US20020022636A1 (en) | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| JP2002515488A (ja) | 1998-05-15 | 2002-05-28 | ギルフォード ファーマシューティカルズ インコーポレイテッド | カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法 |
| WO2000042025A1 (en) | 1999-01-14 | 2000-07-20 | Meiji Seika Kaisha, Ltd. | Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives |
| AU3076700A (en) | 1999-01-26 | 2000-08-18 | Ono Pharmaceutical Co. Ltd. | 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient |
| DE19918211A1 (de) | 1999-04-22 | 2000-10-26 | Basf Ag | Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung |
| DE19920936A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| DE19921567A1 (de) | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
| JPWO2001079184A1 (ja) | 2000-04-18 | 2004-03-18 | 住友製薬株式会社 | 置換ピペラジン類 |
| WO2002044157A2 (en) | 2000-12-01 | 2002-06-06 | Iconix Pharmaceuticals, Inc. | Parb inhibitors |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| ES2282410T3 (es) * | 2001-05-08 | 2007-10-16 | Kudos Pharmaceuticals Limited | Derivados de isoquinolinona como inhibidores de parp. |
| JPWO2002094790A1 (ja) | 2001-05-23 | 2004-09-09 | 三菱ウェルファーマ株式会社 | 縮合ヘテロ環化合物およびその医薬用途 |
| AUPS019702A0 (en) * | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| ES2380917T3 (es) * | 2002-10-01 | 2012-05-21 | Mitsubishi Tanabe Pharma Corporation | Compuestos de isoquinolina y su uso medicinal |
-
2003
- 2003-11-21 AT AT03774144T patent/ATE540928T1/de active
- 2003-11-21 CA CA2507027A patent/CA2507027C/en not_active Expired - Fee Related
- 2003-11-21 TW TW092132796A patent/TW200412959A/zh not_active IP Right Cessation
- 2003-11-21 AU AU2003284632A patent/AU2003284632A1/en not_active Abandoned
- 2003-11-21 US US10/536,173 patent/US7501412B2/en not_active Expired - Fee Related
- 2003-11-21 ES ES03774144T patent/ES2376166T3/es not_active Expired - Lifetime
- 2003-11-21 WO PCT/JP2003/014904 patent/WO2004048339A1/ja not_active Ceased
- 2003-11-21 EP EP03774144A patent/EP1566380B1/en not_active Expired - Lifetime
- 2003-11-21 JP JP2004555004A patent/JP4567460B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1566380A1 (en) | 2005-08-24 |
| US20060094743A1 (en) | 2006-05-04 |
| EP1566380A4 (en) | 2007-05-30 |
| US7501412B2 (en) | 2009-03-10 |
| CA2507027A1 (en) | 2004-06-10 |
| CA2507027C (en) | 2012-05-08 |
| ES2376166T3 (es) | 2012-03-09 |
| TWI348371B (enExample) | 2011-09-11 |
| JPWO2004048339A1 (ja) | 2006-03-23 |
| WO2004048339A1 (ja) | 2004-06-10 |
| TW200412959A (en) | 2004-08-01 |
| JP4567460B2 (ja) | 2010-10-20 |
| EP1566380B1 (en) | 2012-01-11 |
| AU2003284632A1 (en) | 2004-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE540928T1 (de) | Isochinolinverbindungen und ihre medizinische verwendung | |
| CY1109183T1 (el) | Συντηγμενες ετεροκυκλικες ενωσεις και χρηση αυτων ως αναστολεας hcv πολυμερασης | |
| NO20062950L (no) | 5,7-diaminopyrazolo `43-Dlpyrimidiner med PDE-5 inhiberende aktivitet | |
| CY1110969T1 (el) | 5-υποκατεστημενα-2-φαινυλαμινο-βενζαμιδια ως αναστολεiς μεκ | |
| HRP20050663A2 (en) | Malonamide derivatives as gamma-secretase inhibitors | |
| SG159380A1 (en) | Heteroaryl compounds useful as inhibitors of gsk-3 | |
| NO20054404L (no) | 5,7-Diaminopyrazolo [4,3-D] Pyrimidiner Anvendelige ved behandling av of Hypertensjon | |
| DE602006007012D1 (de) | Pyridinderivate als dipeptedyl-peptidase-hemmer | |
| ATE449099T1 (de) | Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren | |
| TW200635585A (en) | Monocyclic substituted methanones | |
| ATE357453T1 (de) | Comt-inhibitoren | |
| EA200600330A1 (ru) | Замещённые имидазопиримидины для предупреждения и лечения рака | |
| ATE552252T1 (de) | Isochinolinverbindungen und deren medizinische verwendung | |
| ATE492534T1 (de) | 1h-indol-5-ylpiperazin-1-ylmethanonderivate | |
| MX2008002234A (es) | Inhibidores de sulfonamida n-biciclico puenteados de gamma secretasa. | |
| EA200500133A1 (ru) | Производные пирролидина в качестве антагонистов окситоцина | |
| ATE297902T1 (de) | Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren | |
| MXPA04005554A (es) | Benzotiazoles. | |
| DE602006014022D1 (de) | 5-substituierte indol-2-carbonsäureamidderivate | |
| CY1108241T1 (el) | Πυριδυλσουλφοναμιδο πυριμιδινες για την θεραπεια της διαβητικης νεφροπαθειας | |
| NO20016402D0 (no) | Trisykliske forbindelser med spiro-kobling | |
| IL184439A0 (en) | 2,5-disubstituted phenyl methanone derivatives as glycine transporter 1 | |
| EA200700322A1 (ru) | Оксазолидиноны, содержащие оксиндолы, в качестве антибактериальных агентов | |
| NO20054086L (no) | Depigmenteringsmidler | |
| WO2007000392A3 (en) | Chloro-substituted guanidines |